Literature DB >> 18547366

A DNA adjuvant encoding a fusion protein between anti-CD3 single-chain Fv and AIMP1 enhances T helper type 1 cell-mediated immune responses in antigen-sensitized mice.

Byeong Cheol Lee1, Insug O'Sullivan, Eugene Kim, Sang Gyu Park, Seung Yong Hwang, Daeho Cho, Tae Sung Kim.   

Abstract

T helper type 1 (Th1) cell-mediated immune responses contribute to host defences against intracellular pathogen infections and cancer. Previously, we found that aminoacyl tRNA synthetase-interacting multifunctional protein 1 (AIMP1) activated macrophages and dendritic cells to enhance Th1 responses. Herein, we manipulated this property to improve Th1 immune responses in vivo by constructing a mammalian expression plasmid (pAnti-CD3sFv/AIMP1) encoding AIMP1 fused to the anti-CD3 single-chain Fv (sFv), the smallest unit of the antibody that interacts with the CD3epsilon region of the T-cell receptor. Intramuscular injection of ovalbumin (OVA)-sensitized BALB/c mice with pAnti-CD3sFv/AIMP1 DNA adjuvant increased the OVA-specific, interferon-gamma production by their CD4(+) T cells and the levels of anti-OVA immunoglobulin G2a (IgG2a) isotype in their sera. Furthermore, the pAnti-CD3sFv/AIMP1 DNA adjuvant decreased interleukin-4 production and anti-OVA IgE levels in the OVA-injected mice. Importantly, the pAnti-CD3sFv/AIMP1 was more efficient than a mixture of pAnti-CD3sFv and pAIMP1 in inducing OVA-specific Th1 immune responses and also in inhibiting OVA-specific Th2 responses during antigen priming. These studies indicated that the pAnti-CD3sFv/AIMP1 fusion DNA adjuvant enhanced Th1 immune responses in antigen-sensitized mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18547366      PMCID: PMC2632698          DOI: 10.1111/j.1365-2567.2008.02880.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  The novel cytokine p43 induces IL-12 production in macrophages via NF-kappaB activation, leading to enhanced IFN-gamma production in CD4+ T cells.

Authors:  Eugene Kim; Seung Hyun Kim; Sunghoon Kim; Tae Sung Kim
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 2.  DNA vaccines: recent developments and future possibilities.

Authors:  Margaret A Liu; Britta Wahren; Gunilla B Karlsson Hedestam
Journal:  Hum Gene Ther       Date:  2006-11       Impact factor: 5.695

3.  A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months.

Authors:  Cemaine Tsang; Shawn Babiuk; Sylvia van Drunen Littel-van den Hurk; Lorne A Babiuk; Philip Griebel
Journal:  Vaccine       Date:  2007-03-22       Impact factor: 3.641

Review 4.  Chemical adjuvants for plasmid DNA vaccines.

Authors:  John R Greenland; Norman L Letvin
Journal:  Vaccine       Date:  2007-02-20       Impact factor: 3.641

Review 5.  Immunoregulation by targeting T cells in the treatment of allergy and asthma.

Authors:  Mark Larché
Journal:  Curr Opin Immunol       Date:  2006-09-28       Impact factor: 7.486

Review 6.  Novel vaccines and adjuvants for allergen-specific immunotherapy.

Authors:  Reto Crameri; Claudio Rhyner
Journal:  Curr Opin Immunol       Date:  2006-09-28       Impact factor: 7.486

Review 7.  Th1 memory: implications for vaccine development.

Authors:  Kathryn E Foulds; Chang-you Wu; Robert A Seder
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

8.  Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.

Authors:  Yue Zhang; Daiko Wakita; Kenji Chamoto; Yoshinori Narita; Naoki Matsubara; Hidemitsu Kitamura; Takashi Nishimura
Journal:  Int Immunol       Date:  2006-12-22       Impact factor: 4.823

Review 9.  The molecular mechanisms that control function and death of effector CD4+ T cells.

Authors:  Binfeng Lu
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 10.  DNA vaccines against mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Future Microbiol       Date:  2006-06       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.